SAREPTA THERAPEUTICS, INC. (SRPT) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD $847.62M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD $838.16M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD $828.97M; Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
SAREPTA THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Face Amount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger pure | Notes Payable, Current USD | Long-term Debt, Excluding Current Maturities USD | Line of Credit Facility, Commitment Fee Percentage pure | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Conversion Ratio pure | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $847.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $910.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $838.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $878.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $828.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $864.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 98.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $41.60M | $204.14M | $43.55M | $43.55M | $937.07M | (m) | (m) | $1.27B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $140.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · 98.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $0.00 | $35.22M | $484.97M | $29.35M | $29.35M | $631.43M | (m) | $1.21B | $879.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.14B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.25B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | $14.38M | $14.38M | $1.16B | (m) | (m) | (m) | (m) | $1.19B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $91.59M | $1.23B | $14.38M | $14.38M | $1.16B | (m) | (m) | (m) | $92.35M | $1.29B | $1.48B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $91.50M | $1.23B | $14.38M | $14.38M | $1.16B | (m) | (m) | (m) | $99.54M | $1.29B | $1.69B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $105.59M | $1.24B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $105.48M | $1.24B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.32B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $121.81M | $14.38M | $14.38M | $1.16B | (m) | (m) | (m) | $1.31B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.24B | $121.81M | $14.38M | $14.38M | (m) | (m) | (m) | $794.00K | $1.32B | $1.48B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.24B | $105.85M | $0.00 | $0.00 | (m) | (m) | (m) | $0.00 | $1.26B | $1.45B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.23B | $105.85M | $0.00 | $0.00 | (m) | (m) | (m) | $0.00 | $1.26B | $1.59B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $105.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $1.54B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $0.00 | $419.37M | $1.15B | $0.00 | $0.00 | $0.00 | (m) | $1.57B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2022-09-30 | (m) | $1.54B | $0.00 | $419.37M | $0.00 | $0.00 | (m) | (m) | $0.00 | $1.57B | $1.90B | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2021-12-31 | (m) | $563.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.42B | (m) | (m) | (m) | (m) | (m) | (m) | $16.80M |
| 2021-12-31 | (m) | (m) | $0.00 | $250.00M | $869.99M | $0.00 | $0.00 | $0.00 | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $250.00M | $869.99M | (m) | (m) | (m) | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $250.00M | $869.99M | (m) | (m) | (m) | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | $250.00M | $869.99M | (m) | (m) | (m) | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | $250.00M | $869.99M | (m) | (m) | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.39B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 1.75% | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $250.00M | $570.00M | (m) | (m) | $820.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $952.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $420.55M | (m) | (m) | (m) | (m) | (m) | $570.00M | (m) | $570.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $415.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $439.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $430.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $431.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $6.33M | $10.00M | $10.00M | $5.00M | (m) | $570.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-11-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.36% | (m) |
| 2017-09-30 | (m) | $37.74M | (m) | $6.39M | $11.61M | $10.86M | $5.98M | (m) | $2.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $17.67M | $10.99M | $5.29M | $171.00K | $171.00K | $172.00K | $880.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.49M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $26.84M | $9.17M | $10.99M | $5.29M | $171.00K | $172.00K | $1.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.45M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.91M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $99.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.83M | $1.45M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.49M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $98.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.48M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $7.10M | $2.69M | $2.67M | $171.00K | $171.00K | $171.00K | $1.22M | (m) | $5.00M | (m) | (m) | (m) | (m) | (m) | 4.75% | (m) | (m) |
| 2014-09-30 | $97.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.42M | $1.50M | (m) | (m) | (m) | (m) |
| 2014-06-30 | $96.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52M | (m) | (m) | (m) | (m) |
| 2014-03-31 | $94.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.55M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $92.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.58M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.67M | $92.00K | $98.00K | $103.00K | $108.00K | $114.00K | $1.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 4.75% | (m) | (m) |
| 2013-09-30 | $91.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.60M | (m) | (m) | (m) | (m) |
| 2013-06-30 | $90.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.62M | (m) | (m) | (m) | (m) |
| 2013-03-31 | $90.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.65M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $89.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.67M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.76M | $89.00K | $93.00K | $98.00K | $103.00K | $108.00K | $1.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 4.75% | (m) | (m) |
| 2012-09-30 | $88.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.69M | (m) | (m) | (m) | (m) |
| 2012-06-30 | $87.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.71M | (m) | (m) | (m) | (m) |
| 2012-03-31 | $86.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.74M | (m) | (m) | (m) | (m) |
| 2011-12-31 | $85.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.76M | (m) | (m) | (m) | (m) |
| 2011-09-30 | $84.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.78M | (m) | (m) | (m) | (m) |
| 2011-06-30 | $83.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.80M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $81.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.84M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |